Teladoc Health (NYSE:TDOC) issued its quarterly earnings data on Wednesday. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.11), MarketWatch Earnings reports. The company had revenue of $241.03 million for the quarter, compared to the consensus estimate of $220.49 million. Teladoc Health had a negative net margin of 13.22% and a negative return on equity of 10.23%. The firm’s revenue was up 85.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.41) earnings per share.

TDOC traded down $4.09 during trading hours on Friday, reaching $232.98. The company’s stock had a trading volume of 73,602 shares, compared to its average volume of 1,610,258. Teladoc Health has a 52 week low of $54.58 and a 52 week high of $239.44. The company’s 50-day moving average is $205.93 and its 200-day moving average is $158.00. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. The firm has a market cap of $17.29 billion, a PE ratio of -185.38 and a beta of 0.44.

In other Teladoc Health news, SVP Andrew Turitz sold 2,778 shares of the company’s stock in a transaction on Friday, June 19th. The stock was sold at an average price of $200.00, for a total value of $555,600.00. Following the transaction, the senior vice president now directly owns 6,793 shares of the company’s stock, valued at approximately $1,358,600. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William H. Frist sold 370 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $180.00, for a total value of $66,600.00. Following the completion of the transaction, the director now directly owns 5,788 shares in the company, valued at $1,041,840. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,860 shares of company stock worth $35,572,671. 3.42% of the stock is owned by company insiders.

A number of research firms recently issued reports on TDOC. SVB Leerink lifted their price target on Teladoc Health from $227.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday. Craig Hallum lifted their price target on Teladoc Health from $140.00 to $150.00 and gave the company a “hold” rating in a report on Thursday, April 30th. Credit Suisse Group lifted their price target on Teladoc Health from $165.00 to $225.00 and gave the company a “neutral” rating in a report on Thursday. Barclays boosted their price objective on Teladoc Health from $200.00 to $230.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, JPMorgan Chase & Co. boosted their price objective on Teladoc Health from $240.00 to $266.00 and gave the stock an “overweight” rating in a report on Thursday. Fifteen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $195.04.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: What is the Dividend Aristocrat Index?

Earnings History for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.